<SEC-DOCUMENT>0001493152-20-007563.txt : 20200501
<SEC-HEADER>0001493152-20-007563.hdr.sgml : 20200501
<ACCEPTANCE-DATETIME>20200501172926
ACCESSION NUMBER:		0001493152-20-007563
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200501
DATE AS OF CHANGE:		20200501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RITTER PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		20842001

	BUSINESS ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310-203-1000

	MAIL ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): May 1, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>RITTER
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-37428</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>26-3474527</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jurisdiction
        of incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1880
Century Park East, Suite 1000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
    Angeles, California</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>90067</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>(310) 203-1000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Registered Pursuant to Section 12(b) of the Exchange Act:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Each Exchange on Which Registered</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, par value $0.001</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RTTR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 3.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 3.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
2.02. Results of Operation and Financial Condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;), issued a press release announcing the financial results
for the first fiscal quarter ended March 31, 2020, entitled &ldquo;Ritter Pharmaceuticals Reports Financial Results for the First
Quarter Ended March 31, 2020 - Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway&rdquo; (the
&ldquo;Press Release&rdquo;). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of
Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18.
Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing
under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such
filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Important
Additional Information Will be Filed with the SEC</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2020, Ritter filed a registration statement on Form S-4 with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
that included a joint proxy and consent solicitation statement/prospectus. The registration statement on Form S-4 was declared
effective on April 9, 2020. The final joint proxy and consent solicitation statement/prospectus was filed with the SEC on April
9, 2020 and was first sent to the stockholders of Ritter and Qualigen on or about April 9, 2020. Each party may file other documents
with the SEC in connection with the merger. INVESTORS AND STOCKHOLDERS OF RITTER AND QUALIGEN ARE URGED TO READ THESE MATERIALS
CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN, OR WILL CONTAIN, IMPORTANT INFORMATION ABOUT RITTER, QUALIGEN, THE MERGER
AND RELATED MATTERS. Investors and stockholders may obtain free copies of the documents filed with the SEC through the website
maintained by the SEC at www.sec.gov. Investors and stockholders may also obtain free copies of the documents filed by Ritter
with the SEC by contacting Ritter by mail at Ritter Pharmaceuticals, Inc., 1880 Century Park East, Suite 1000, Los Angeles, CA
90067, Attention: John Beck. Investors and stockholders are urged to read the definitive proxy statement/prospectus/information
statement and the other relevant materials when they become available before making any voting or investment decision with respect
to the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Offer or Solicitation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Participants
in the Solicitation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
and its directors and executive officers and Qualigen and its directors and executive officers may be deemed to be participants
in the solicitation of proxies from the stockholders of Ritter in connection with the Merger. Information regarding the special
interests of these directors and executive officers in the merger is included in the joint proxy and consent solicitation statement/prospectus
referred to above. Additional information about Ritter&rsquo;s directors and executive officers is included in Ritter&rsquo;s
Annual Report on Form 10-K, filed with the SEC on March 31, 2020, as amended on April 24, 2020. These documents are available
free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Ritter at the address above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release, dated May 1, 2020, entitled &ldquo;Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020 - Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway&rdquo;</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RITTER
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><I>/s/ Andrew J. Ritter</I></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    J. Ritter</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 1, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 52.5pt; width: 158.25pt"></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ritter
Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LOS
ANGELES </B>(May 1, 2020) &ndash; Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (&ldquo;Ritter Pharmaceuticals&rdquo;, Ritter&rdquo;
or the &ldquo;Company&rdquo;), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal
diseases, today reported financial results for the first quarter ended March 31, 2020.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, Ritter and Qualigen, Inc. (&ldquo;Qualigen&rdquo;),&nbsp;a privately-held company focused on the development and
commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its
flagship FastPack<SUP>&reg;</SUP> diagnostic platform, announced&nbsp;that the two companies had entered into a definitive&nbsp;&ldquo;reverse
merger&rdquo;&nbsp;agreement. Under the&nbsp;terms of the merger&nbsp;agreement, Qualigen will become a wholly-owned subsidiary
of Ritter. Upon completion of the merger, Ritter will change its name to Qualigen Therapeutics, Inc., and will focus on the development
of Qualigen&rsquo;s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate
its revenue-generating diagnostic business.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
special meeting of Ritter stockholders to vote on certain matters related to the proposed merger will be held virtually on May
14, 2020, at 9:00 a.m., Pacific Time. As described in the proxy materials for the special meeting, Ritter stockholders of record
as of the close of business on March 26, 2020, which is the record date for the special meeting, will be entitled to participate
in the special meeting.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;We
are entering the home stretch in our effort to complete the potential merger with Qualigen, a transaction that we believe could
provide meaningful value for Ritter stockholders,&rdquo; said Andrew J. Ritter, Ritter Pharmaceuticals&rsquo; Chief Executive
Officer. &ldquo;We encourage those who have not yet voted to take a few minutes to vote by phone, internet or mail on this important
transaction as the meeting date is less than two weeks away. When voting, please remember that the merger cannot be consummated
unless each of the proposals being voted on at the special meeting is approved.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Results for the First Quarter Ended March 31, 2020</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s net loss, and net loss per share attributable to common stockholders for the first quarter ended March 31, 2020
was $1.7 million, or $0.05 per share, compared to $4.7 million or $0.58 per share, for the same period in 2019. Net loss for the
first quarter ended March 31, 2020, included non-cash, stock-based compensation expense of approximately $56,000, compared to
approximately $146,000 for the same period in 2019. As of March 31, 2020, the Company had cash and cash equivalents of approximately
$6.0 million compared to $1.7&nbsp;million in cash, cash equivalents and investment in marketable securities as of December 31,
2019.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operations</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continues to explore monetization opportunities for RP-G28 for the treatment of lactose intolerance, including exploring
a variety of commercial routes. In April, the RP-G28&rsquo;s Phase 2b 003 study&rsquo;s data was published in <I>Nutrients</I>,
under the title: <U>Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients</U>. Lead
author was William Chey, M.D., Co-Director of the Michigan Bowel Control Program at Michigan Medicine.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>How
to Vote</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
stockholders of record should follow the instructions on their proxy card to vote. They may call proxy solicitor Georgeson toll-free
at (866) 357-4029 to vote over the phone, or by following the instructions in the proxy card previously delivered to them, they
may vote online or by completing, signing and dating the proxy card and mailing it in the postage-paid envelope that was previously
provided.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
stockholders who hold their shares in a brokerage or bank account (in &ldquo;street name&rdquo;) may vote online or by phone,
by following the instructions provided in the voting instruction form previously delivered to them, or by completing, signing
and dating the voting instruction form and mailing it in the postage-paid envelope that was previously provided.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have questions or require assistance in voting your proxy, please call our proxy solicitor Georgeson toll-free at <B>(866)
357-4029 </B>or email <B>info@ritterpharma.com</B> for assistance.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Attending
the Virtual Special Meeting</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
special meeting of Ritter stockholders to vote on certain matters related to the proposed merger will be held virtually on May
14, 2020, at 9:00 a.m., Pacific Time. Stockholders of record will be able to attend the special meeting online by visiting <I>www.virtualshareholdermeeting.com/RTTR2020
</I>on the date of the meeting. To be admitted to the virtual meeting, stockholders must enter the control number found on their
proxy card or voting instruction form. Street name holders must obtain a proxy from the broker, trustee or nominee that holds
their shares in order to attend the special meeting.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Ritter Pharmaceuticals</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops innovative therapeutic products that modulate the gut microbiome
to treat gastrointestinal diseases. On January 15, 2020, the Company entered into an Agreement and Plan of Merger with Qualigen,
pursuant to which a wholly-owned subsidiary of Ritter will merge with and into Qualigen, with Qualigen surviving as a wholly-owned
subsidiary of Ritter Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of Ritter Pharmaceuticals&rsquo; management. Any statements contained herein
that do not describe historical facts, including statements related to the proposed merger with Qualigen are forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results, performance and achievements
to differ materially from those discussed in such forward-looking statements. Some of the factors that could affect actual results
are included in the reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
from time to time, as well as Ritter&rsquo;s final joint proxy and consent solicitation statement/prospectus that was filed with
the SEC on April 9, 2020. Ritter cautions readers not to place undue reliance on any forward-looking statements, which speak only
as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as
otherwise required by law, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Important
Additional Information About the Proposed Merger</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
communication is being made in respect of the proposed merger involving Ritter Pharmaceuticals, Inc. and Qualigen, Inc.&nbsp;
Ritter filed a registration statement on Form S-4 (File No. 333-23635) with the SEC. The Registration Statement on Form S-4 was
declared effective on April 9, 2020. The final joint proxy and consent solicitation statement/prospectus was filed with the SEC
on April 9, 2020 and was first sent to the stockholders of Ritter and Qualigen on or about April 9, 2020. The final joint proxy
and consent solicitation statement/prospectus contains important information about Ritter, Qualigen, the proposed merger and related
matters. STOCKHOLDERS ARE URGED TO READ THE FINAL JOINT PROXY AND CONSENT SOLICITATION STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY, AS THEY CONTAIN IMPORTANT INFORMATION THAT
STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER AND RELATED MATTERS. In addition to receiving the final
joint proxy and consent solicitation statement/prospectus and proxy card or voting instruction form by mail, stockholders will
also be able to obtain the final joint proxy and consent solicitation statement/prospectus, as well as other filings containing
information about Ritter, without charge, from the SEC&rsquo;s website (http://www.sec.gov) or, without charge, by directing a
written request to: Ritter Pharmaceuticals, Inc., 1880 Century Park East, Suite 1000, Los Angeles, CA 90067, Attention: Corporate
Secretary.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Offer or Solicitation</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
communication shall not constitute an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation
of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer
of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933,
as amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants
in the Solicitation</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from
the stockholders of Ritter Pharmaceuticals in connection with the proposed merger. Information regarding the special interests
of these directors and executive officers in the proposed merger has been included in the joint proxy and consent solicitation
statement/prospectus. Additional information about Ritter Pharmaceuticals&rsquo; directors and executive officers is included
in Ritter Pharmaceuticals&rsquo; Annual Report on Form 10-K, filed with the SEC on March 31, 2020, as amended on April 24, 2020.
These documents are available free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Ritter Pharmaceuticals
at the address above.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Contact:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Beck<BR>
310-203-1000<BR>
<U>john@ritterpharma.com</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RITTER
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended<BR>
 March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating costs and expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,820</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">3,574,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,209,468</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,153,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,215,079</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,777,057</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,215,079</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,777,057</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Settlement of accounts payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">535,087</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8213;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">547,707</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">71,291</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,667,372</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,705,766</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive gain:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Unrealized gain on debt securities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8213;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,511</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,667,372</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,704,255</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.58</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,910,882</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,055,921</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RITTER
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">5,952,893</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,699,971</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued interest receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8213;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">771</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">176,735</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">509,519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,129,628</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,210,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,032</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">478,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">478,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Total other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">543,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,107</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,192</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,687,541</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,797,024</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,290,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,417,317</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,258</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,854</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,672,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,697,046</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Series B preferred stock, $0.001 par value; 6,000 shares authorized; 0 and 1,850 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8213;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,288,956</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Series C preferred stock, $0.001 par value; 1,880 shares authorized; 240 shares issued and outstanding as of March 31, 2020 and December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common stock, $0.001 par value; 225,000,000 shares authorized, 45,713,862 and 19,108,331 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,729,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,885,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(82,000,536</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(80,333,164</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,015,138</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,099,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,687,541</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,797,024</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, F@# 2(  A$! Q$!_\0
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MZ'_&F_\ ":3H?FLXV^CD5A2FJ;GFO'GF&)CM-_A_D>I' X=[Q.L7QP/X]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:YHNZ%HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\6^(U\+Z(VH&W,[%Q&B;MHW
M$'DGTXKPK7O%.K^)9MU]<'R0<I GRQK^'<^YR:]6^+?_ ")R?]?:?R:O%X8]
MT8->YEM*'L_:-:W/!S2K4]I[-/2Q"$Q2XJQY-'DUZESR.61M?#__ )'S2_\
MKHW_ * U>N7;;II&]6)KR3P%A?'VF9X_>L/_ !QJ]LET21R2LR\^HKY;B"G.
M=2"BKZ'U?#\XPIRYGU.>E-493UKHY?#MVWW983]2?\*I2^&M1/01'Z/7R57"
MU_Y&?5T\31_F1S<IJ"MR7PQJ_P##;!OI(O\ C6KH_A)5VSZD,MU$(/ ^I[_2
MN.& Q%6?+RM>NB.F6-H4X<W-?T,#2]#N]5?]VNR'/S2L.!]/4UW.EZ)::4F8
MDWRD?-*P^8_X"I-0U+3]#L#<7L\5K;H,#/'X*!U/L*\B\4_$^^U7?9Z.'M+0
M\&3_ ):R#ZC[H^G/OVKZK+,D47>*N^[V7I_5SYK,<YTM)V79;_/^K'>>*OB!
MIGAP/;PD7FH#CR4;A#_MGM].OTKQ?6]?U/Q'>?:-0N"^#\D8X2,>BCM_/WJD
MMNQ^9^IJ3R:^MP^$IT%IJ^Y\EB<75KNST78KA<48JQY-'DUUW.+ED5\48JQY
M-'DT7#E97VT;:L>31Y-%PY9$$;RV\JS02/'*ARKHQ#*?4$5Z=X*^)-_<:A:Z
M1JL?VDS.(H[A>'4G@;AT(]^OUKSCR:T?"8QXVTD?]/<?\ZY\32A4IOF6R9U8
M6K4IU%RNUVCZ/%+2"EKY<^K$)Q7%ZK\3]%T?5+C3[BUU!IH'V,T<:%2?;+BN
MU-?.?C8;O'.JJ>]P?Y"NW T(5IN,^B.''XB=""E#N>E_\+A\/_\ /GJ?_?N/
M_P"+H_X7#X?_ .?/4_\ OW'_ /%UX[]F'I1]F'I7I_V=A_/[SRO[3Q/E]Q[%
M_P +A\/_ //GJ?\ W[C_ /BZ/^%P^'_^?/4_^_<?_P 77COV8>AH^S#TH_L[
M#^?WA_:>)\ON/98OB[X=D;#0:A&/5HE(_1C6WI_CSPUJ;!(=5A20\;)P8SG_
M ($ *^?_ +,/2FM:GL3^-3++:#V;1<<TKKXDF?4:L&4%2"",@CO3@<U\Z^'_
M !?K/A>91#,TMIGYK:4DH1[?W3[C]:]R\.^(K+Q+IBWEFV"/EEB8_-&WH?Z'
MO7F8G!SH:O5=SU,-C85]-GV-BJVH7L>G:=<WLJLT=O$\SA.I"@DX]^*L@YK)
M\4?\BEK/_7C/_P"BVKF@KR29U3=HMKL<I_PN'P__ ,^>I_\ ?N/_ .+H_P"%
MP^'_ /GSU/\ []Q__%UXQ#&)-V>V*E^S#TKW_P"SL/Y_>?/?VGB?+[CV+_A<
M/A__ )\]3_[]Q_\ Q==I_:</]B_VIM?R/L_VC;@;MNW=ZXSCWKYDFC$9''6O
MH;_FGF>_]E?^TJXL;A*5+DY.K.[!8NK6Y^?HNQ@?\+A\/_\ /GJ?_?N/_P"+
MH_X7#X?_ .?/4_\ OW'_ /%UXQ#&)">.E2_9AZ5V_P!G8?S^\X?[3Q/E]Q[%
M_P +A\/_ //GJ?\ W[C_ /BZ/^%P^'_^?/4_^_<?_P 77COV8>E'V8>E']G8
M?S^\/[2Q/E]Q[%_PN'P__P ^>I_]^X__ (NC_A</A_\ Y\]3_P"_<?\ \77C
MOV8>E'V8>E']G8?S^\/[2Q/E]Q[%_P +A\/_ //GJ?\ W[C_ /BZ/^%P^'_^
M?/4_^_<?_P 77COV8>E-E@"1EL=*/[.P_G]X?VGB?+[CZ,\-^);/Q1ITE[8Q
M3QQ)*8B)E )( .>">/F%8>J_$_1='U2XT^XM=0:6W?8QCC0J3[9<53^#_P#R
M*5U_U_/_ .BXZ\U\:KN\=:JI_P"?@_R%<5'"4IXB=-[+_@'=6Q=6&&A46[\O
M4]*_X7#X?_Y\]3_[]Q__ !='_"X?#_\ SYZG_P!^X_\ XNO'?LR^E'V8>E=O
M]G8?S^\X?[2Q/E]Q[%_PN'P__P ^>I_]^X__ (NC_A</A_\ Y\]3_P"_<?\
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M%6GF6$>5<QX$UNQR4/J/4'UKH:\B<)0DXR5FCV(3C.*E%W3"BBBI*.#^+?\
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M =2:[8TE%W..>(E-<MCZ$^':LO@/2PYR=KG\/,;'Z5I>*/\ D4M9_P"O&?\
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M3_GZ@_[^"C[5:?\ /U!_W\%>?8HH^K+N/Z\_Y3O6U&P3K>0?@X-5I->TV/\
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M?YBN@KG_ !S_ ,B1JW_7 _S%:T?XL?5?F95_X4O1_D?.5%%%?6'R 5]3VO\
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M>?=CG\!7O2Q=&+TU<;)?.USP8X2M):Z*5V_E>QK_  NNOM'@>V3.3!+)&?\
MOK=_[-795Q?PWT+5?#VE7EGJ<"Q;YQ+'M<-G*@'H?]D5V9KR,5;VTG%W5SU\
M+S>QBI*SL<3\4-:_LWPHUJC8FOF\D8/.SJQ_+ _X%7E=JDOA34-!UE)ED,J"
M=T1AE1N(*GZH1_WU7H/C3PGKGBGQ7:D1!-)A"Q^9YJY )R[!>N>WX"JVM_".
MUBTMY-%GNYKT%=L=Q(FUAGGG:,''/7M7HX:K1I4HPE+XM_GIKV/-Q5*O5JRJ
M1C\.WRUT[GI\,J3PI+$P:-U#*P[@\@T\U@^#+74[#PS;66K1".XM\QC#AMR#
M[O3VX_"M\UY,XJ,FD[GKPDY13:L>)7T">)_B^]CJ;L+<3M$%SCY$4D*/J1_X
M\:]1M?">B6&H6]]96$=M<0 JK1?+D$$$$=^O7K7+>-O %WJ6J#6]#F$=]D&2
M,OLW,O1E;LW ]/K3?"VF^.3XDM+CQ"\AL[=7P&GC()*D#A#R>>IKT:LE4I1E
M"=DE:W];W/.I1=*K*,X7;=[_ -;6/1A7-?$+_D1-5_ZYK_Z&M=,*P_&&G7.K
M>%;^PLT#W$R@(I8#)# ]3]*X*+2J1;[H[ZZ;I22[,\@\(:BD+65J_AFVO-]R
MH-X\19ERP[X[5[T*\FT'0_B)H:06=L8H;$2AG3="W!(W<G)KUD5UX^4933BT
M_1W_ .&.3+XRC!J2:]5;_AP->1?!I@+W5UR,F.,@?BU>NFO(F\$^+?"^N3W7
MAAEE@ERJG>@(0G.UE?CCU%3A7%TZE-NS=K7\BL4I1J4ZB3:5[V\R/_FNW_;?
M_P!HU["*\T\&>"-9M_$K>(/$#J+D%F5-X9F=@06.W@#!/ _3%>EBEC9Q<HQB
M[V20\%"2C*4E:[;*]]86FI6QM[VWCN(202DB[AD=.*\?\*:1IUW\4-8L+BR@
MEM(GN0D+H"JXDP,#V%>T&O/?#7A;5M-^(FJ:Q<VZK97#SF-Q(I)W29' .>E/
M#5>6G43=M-/6X8JES5*;2OKKZ6/0(HD@B2*-0D:*%50,  =!3Z!03BN([3QW
MX-_\A?4_^N"_^A5[$*\X^&_A/5_#FH7LVI6Z1)+$JH5D5LD'/8UZ.*[,?.,Z
M[<7=:'%@(2A02DK/4\X^,-[/#H=C:1DB*XF)DQWVC(!_$Y_"KGA7P1X>F\)6
M4EQ8Q74MU DLDSGYLL,X!'W<=./2M_Q7X;M_%&C-8S/Y<BMYD,N,[''\QR0:
M\U@\,?$;1X'TW3Y7^QY.&BN4"C/4KN(9?PQ6U&2GAU3C/E:?I<QK1<,0ZDH<
MR:MWL>P6ELEG9PVT6?+AC6-<]< 8%2FJNE02VNDV=O-_K8H$1^<_,% /ZU:;
M@=,UYTMV>E'9'D7Q3U%M3\0Z=X?@D4!"I<DX D<X&?H.?^!57\!W0\-_$&\T
M5IA);W#-"C@@ABN2C9'J,CZM5RU^'6J:]XEOK_Q(KVL$Y:0>1,C-N)X7O@ ?
MR%,UGX7WNEW]E=>&&EG,;;V-Q*@9'4@J1PO^17LQJ4%3^K\W3Y7WW/$E"NZG
MUCEZ_.VVQZX*6HX&D>!&E3RY"H+)G.TXY&:D)Q7BGN'COP;_ .0OJ?\ UP7_
M -"KV$5XMHWA#Q]X?EEETN.*!Y5"N?,B;('/\6:]:T0:@-&M1JS!K\)^_(V\
MM_P'C\J[\P495/:1DFF>?E[E&G[.46FNY?->$:CIVL>$?%-WJ5UH\=]:M)(P
MDGA\R)E8YSG^%OK7NYKRF_TSXEH]_;12)<VUVS[BDL>T!LY"[R&48/2E@9\K
MDFU9]W;[AX^',HM)W7;7[SJ_ .OZ9K>D2QZ=8K8&W?\ >VR<JI8DY!]#@_3%
M%1?#WPE<>%]-N6O70W=TRET0Y"*N<#/<\FBL,3R>UE[-W1T8;G]E'VBLSL:*
M**P-PHHHH *3%+10!CZIX=L]2!?;Y,Y_Y:(.OU'>N+U/1+S2V)E3=%GB5.5_
M'T/UKTRD90RE6 ((P0:\[%Y91Q'O+W9=U^J.[#9A5HZ/5=CR*BNXU7PC;W&Z
M6Q(@D//EG[A_PKC[RQN;";RKF)HV[9Z'Z'O7S6)P5;#/WUIWZ'OX?%TJZ]UZ
M]NITO@S4,&73W/7]Y'_4?U_.N#^+6D_8_$L6H(N([V(;C_MI@']-M:]E=/97
ML-RF<QL&P.X[C\JVOBC8)J/@L7T8#&UD296'=&^4_AR#^%?5<,8S54WTT^3V
M_$^9XDPEXN:ZZ_-;_@>'445W'AGX9ZKK6RXOLV%F>077]XX]E[?4_D:^YJ58
M4H\TW8^)I49U9<L%<XRUM;B]N$M[6&2:9SA4C4L3^ KT[PS\)GDV77B"0HO4
M6D3<G_>8=/H/S%>AZ%X:TKP];^5I]LJ,1AY6^:1_JW].E:]>-B,RG/W:6B[]
M?^ >UALLA#WJNK[=/^"5K*PM=-M4MK*WC@@7HD:X'_Z_>K-%%>8VV[L]1))6
M04444AA1110 4444 %)CWI:* "BBB@ I,4M% "8I<444 )BC%+10 F*6BB@!
M,48I:* $ Q2T44 )BC%+10 4&BB@!,>]&*6B@! ,4M%% !28I:* "@T44 )B
MEHHH #28I:* #%%%%  128I:* "BBB@!,4M%% !28I:* #%%%% "8HQ2T4 %
M%%% "8I0*** "DQ2T4 %%%% !1110 4444 %%%% !1110 $9J&YM(+N$Q7$2
MR(>S"IJ*32:LQIM.Z.+U7PA)%NETYC(O7RF/S#Z'O_GK5NPM9-8\'WFDW*/&
MYC>W!D4C&1P?P)_2NH- KCH8*G0K^VI:>70Z:V+G6H^RJZ^?4Y3PS\/](\.[
M)RGVN^'_ "WF4?*?]E>B_P _>NKQ2BBO0J5)U)<TW=G%3IPIQY8*R"BBBH+"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
